Riskpilot← Back to searchSign inGet full accessAmniotics AB (publ)
ABDissolvedOrg 5590246558Research and experimental development on biotechnology · NACE 7211Est. 20150 employees
Revenue 2023
SEK 0
EBITDA margin
—
+40% vs 2022
Equity ratio
59.6%
Financial strength
Net profit 2023
SEK -30,9M
+36% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -26,8M | +40% |
| Net profit | SEK -30,9M | +36% |
| Total assets | SEK 26,1M | -10% |
| Equity | SEK 15,5M | +948% |
| Employees | 0 | — |
Legal name
Amniotics AB (publ)
Org number
5590246558
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
1 september 2015
Share capital
SEK 6 505 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Larsson, Marcus Kåre Torleif i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolagets verksamhet ska vara att tillverka, utveckla, idka handel med cell-, medicinska-, diagnostiska-, farmaceutiska- och kemiska-tekniska produkter, förvärva, upplåta och överlåta immateriella rättigheter för sådana produkter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | 118 | −2 492 | −6 858 | −10 147 | −29 408 | −51 462 | −44 900 | −26 771 |
| Depreciation & amort. | −0 | −0 | −0 | −281 | −1 586 | −2 153 | −1 793 | −2 301 |
| EBIT | 118 | −2 492 | −6 858 | −10 428 | −30 994 | −53 615 | −46 693 | −29 072 |
| Net financials | −1 | — | −2 | −1 | −3 | −4 | −1 353 | −1 798 |
| Profit before tax | 117 | −2 492 | −6 859 | −10 428 | −30 997 | −53 619 | −48 046 | −30 870 |
| Tax | −26 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 91 | −2 492 | −6 859 | −10 428 | −30 997 | −53 619 | −48 046 | −30 870 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1 805 | 3 263 | 3 921 | 16 619 | 53 451 | 58 088 | 28 917 | 26 086 |
| Equity | 1 626 | 2 907 | 3 124 | 12 909 | 42 186 | 49 530 | 1 483 | 15 539 |
| Long-term debt | 0 | 0 | 0 | 0 | 599 | 0 | 0 | 0 |
| Short-term debt | 179 | 356 | 797 | 3 710 | 10 666 | 8 558 | 27 434 | 10 547 |
| Total debt | 179 | 356 | 797 | 3 710 | 11 265 | 8 558 | 27 434 | 10 547 |
EBITDA margin
-2677100000.0%
This company
15.8%
Market median
-16943670986% vs market
20162023
Equity ratio
59.6%
This company
38.2%
Market median
+56% vs market
20162023
Return on equity
-198.7%
This company
18.4%
Market median
-1180% vs market
20162023
Net profit margin
-3087000000.0%
This company
8.1%
Market median
-38111111211% vs market
20162023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162023
Debt / equity
0.68×
This company
0.62×
Market median
+10% vs market
20162023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MK Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
MS Chief Auditor | Chief Auditor | 2020 | — | — |
KE Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Amniotics AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marcus Kåre Torleif Larsson | Chief Executive Officer | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Kåre Engkilde | Chief Executive Officer | 0 companies |
| Karin Marie Christine Widstrand | Board of Directors | 0 companies |
| Lars Christer Fredrik Fåhraeus | Chairman | 0 companies |
| Lars John Anders Månsson | Board of Directors | 0 companies |
| Lars Lennart Stigsson | Board of Directors | 0 companies |
| Ingrid Ida Margareta Atteryd Heiman | Board of Directors | 0 companies |
| Peter Buhl | Chairman | 0 companies |
| Nils Walter Andreas Herbst | Board of Directors | 0 companies |
| Fredrik Tiberg | Board of Directors | 0 companies |
| Per Åke Antonsson | Board of Directors | 0 companies |
| Christopher Andrew Bravery | Board of Directors | 0 companies |